Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Certara ( (CERT) ) has shared an announcement.
On March 27, 2026, Certara, Inc. disclosed that board member Cynthia Collins plans to resign as a Class II director and member of the Audit Committee, effective May 14, 2026, coinciding with the company’s 2026 annual meeting of stockholders. The company emphasized that Collins’s decision to step down did not arise from any disagreement with Certara regarding its operations, policies or practices, suggesting an orderly governance transition rather than signaling internal conflict.
The departure of an Audit Committee member may prompt Certara to realign board responsibilities or appoint a new director with financial oversight expertise to maintain strong governance. Investors and other stakeholders are likely to monitor how the company addresses this vacancy, as audit committee composition is closely linked to financial reporting quality and regulatory compliance expectations.
The most recent analyst rating on (CERT) stock is a Buy with a $6.50 price target. To see the full list of analyst forecasts on Certara stock, see the CERT Stock Forecast page.
Spark’s Take on CERT Stock
According to Spark, TipRanks’ AI Analyst, CERT is a Neutral.
The score is supported primarily by strong cash generation and a low-risk balance sheet, which reduce downside risk. Offsetting this are weak technical trends, a high P/E valuation, and mixed earnings-call signals including conservative 2026 growth guidance and disclosed execution challenges.
To see Spark’s full report on CERT stock, click here.
More about Certara
Certara, Inc. is a life sciences technology company that provides software and services to support drug development and regulatory decision-making for pharmaceutical and biotech clients. The company focuses on model-informed drug development, pharmacometrics, and related analytics to improve the efficiency and success rates of bringing new therapies to market.
Average Trading Volume: 3,158,369
Technical Sentiment Signal: Sell
Current Market Cap: $903.9M
Learn more about CERT stock on TipRanks’ Stock Analysis page.
Trending Articles:
- “…Overlook a Lack of Earnings Power”: UBS Analysts Target Intel Stock (NASDAQ:INTC), Stock Gains
- “…Significantly Extend the Reach and Lethality of our Fleet”: Boeing Stock (NYSE:BA) Slips Despite Successful MQ-25A Test
- “Direct Result of Your Feedback….” Microsoft Stock (NASDAQ:MSFT) Slips as The Option to Skip Updates Emerges

